The data is intriguing: "in all three indications over 50% of patients have achieved long term survival following treatment with VB-111". It is not statistically significant but it is positive directionally.
Will we see a repeat in ph3? I hope so. That's all that really matters at this point. Ph1 and ph2 data can show wonderful things but they won't matter if ph3 fails.
News 
Market Data 
Discover 
